←
Gregory Lesinski1,366 posts
Gregory Lesinski avatar

Gregory Lesinski

@LesinskiLab

The Lesinski Laboratory is focused on understanding the interactions between the immune system and cancer. opinions are my own. #immunotherapy #GICancer

◷ Joined November 2016▧ 157 Photos and videos
Chrystal Paulos avatar
⟳ Gregory Lesinski retweeted
Chrystal Paulos@Chrystal_Paulos·11h

Expert in CAR/TCR binder design, CRISPR in primary T cells & vectors? Winship Cellular Therapy Initiative at Emory is hiring a senior Academic Research Scientist to train our team and move projects toward the clinic. On-site, Atlanta.
staff-emory.icims.com/jobs/1… #Tcell @LesinskiLab

Chrystal Paulos avatar
⟳ Gregory Lesinski retweeted
Chrystal Paulos@Chrystal_Paulos·11h

Building cancer-killing T cells? 🧬 Winship’s Cellular Therapy Initiative (WCTI) is hiring an Associate Academic Research Scientist. Help investigators build CAR, TCR, ADC & bispecific therapies for solid tumors. On-site Atlanta.
staff-emory.icims.com/jobs/1… #CellTherapy @LesinskiLab

Cholangiocarcinoma Foundation avatar
⟳ Gregory Lesinski retweeted
Cholangiocarcinoma Foundation@curecc·Nov 10

Registration for the 14th Annual Cholangiocarcinoma Foundation Conference is now open. 🎉 Join researchers, clinicians, patients, caregivers, and advocates for a weekend of connection, presentations on the latest advancements in cholangiocarcinoma research, and a community united by hope. The event is in-person only, and everyone is invited to attend the scientific sessions. There will be 1-2 patient- and caregiver-focused breakout sessions on March 23-24.  Register today at: curecca.link/ac2027.

Post attachment
Wungki Park, MD MS avatar
⟳ Gregory Lesinski retweeted
Wungki Park, MD MS@CentralParkWMD·Sep 29

What happens when you actually DEGRADE KRAS G12D in pancreatic cancer? At #AACRPanc26 we shared translational analyses of setidegrasib, the first-generation KRAS G12D degrader. @AstellasUS 15 paired tumor biopsies let us watch the biology change in patients: Successful deep KRAS protein degradation.✏️ →↓ MAPK signaling → tumor-immune remodeling including Fas/FasL, Granzyme B+ CD8 T cells & PD-L1 → distinct primary + acquired resistance biology! → rational mFOLFIRINOX and maybe immune combinations? Parallel virtual patient and patient-derived organoids experiment from @orakldotbio predicting the human clinical trial outcomes independently. What should we do next? Patient → biopsies 💉→ biology 🧫→ model → combination → back to patient Huge thanks to our coauthors, Shilpa Kadam @anup_kasi @MacarullaTeresa and research teams and above all the courageous patients who made this work possible. #KRAS #KRASG12D #PDAC #PancreaticCancer #TranslationalResearch #GRIT #sPARKlab @MSK_DeptOfMed @MSKCancerCenter @CpcrMsk @oncodaily @OncoDailyGI @OncBrothers @PanCAN @lustgartenfdn @Pankind_Aus @NatPancFdn @EileenMOReilly

Post attachmentPost attachmentPost attachmentPost attachment
Gregory Lesinski avatar
Gregory Lesinski@LesinskiLab·Sep 2

Honored to work with urgency on the new @WinshipAtEmory Cellular Therapy Initiative with the one and only @Chrystal_Paulos to help investigators move #celltherapy ideas in #cancerresearch from lab to clinic! #TIL #cartcells #tcells

Winship Cancer Institute of Emory University launches the Cellular Therapy Initiative to accelerate next-generation cancer treatments through research, manufacturing and clinical trials. Learn more ➡️ bit.ly/3Uv2ZFE.

Post attachment
Gregory Lesinski avatar
Gregory Lesinski@LesinskiLab·Jul 11

Congrats to @AyanaTRuffin on this exciting @CR_AACR paper on #celltherapy #CpG #TLR9 collaboration with @IAmDrDex @Chrystal_Paulos @PennCancer @WinshipAtEmory

New from @AyanaTRuffin and our team @PaulosLab @LesinskiLab in Cancer Research: TLR9 agonism boosts T cell therapy by activating B cells that provide critical CD2 costimulation: improving tumor control. A powerful B cell–T cell partnership. 🧬 pubmed.ncbi.nlm.nih.gov/4240…

Post attachment
Gregory Lesinski avatar
Gregory Lesinski@LesinskiLab·Jul 1

Kudos to @HeumannThatcher on this phase 2 @NCICancerTrials of #immunotherapy in #cholangiocarcinoma @hopkinskimmel @WinshipAtEmory @curecc @MarkYarchoan and many others! pubmed.ncbi.nlm.nih.gov/4237…